ABSTRACT: Viral pathogenesis in the infected cell is a balance between antiviral responses and subversion of host-cell processes. Many viral proteins specifically interact with host-cell proteins to promote virus biology. Understanding these interactions can lead to knowledge gains about infection and provide potential targets for antiviral therapy. One such virus is Ebola, which has profound consequences for human health and causes viral hemorrhagic fever where case fatality rates can approach 90%. The Ebola virus VP24 protein plays a critical role in the evasion of the host immune response and is likely to interact with multiple cellular proteins. To map these interactions and better understand the potential functions of VP24, label-free quantitative proteomics was used to identify cellular proteins that had a high probability of forming the VP24 cellular interactome. Several known interactions were confirmed, thus placing confidence in the technique, but new interactions were also discovered including one with ATP1A1, which is involved in osmoregulation and cell signaling. Disrupting the activity of ATP1A1 in Ebola-virus-infected cells with a small molecule inhibitor resulted in a decrease in progeny virus, thus illustrating how quantitative proteomics can be used to identify potential therapeutic targets.
■ INTRODUCTION
Ebola virus causes severe hemorrhagic fever in humans and nonhumans primates. Because of the high mortality rate, potential transmission from person-to-person contact, and the lack of approved vaccines or antiviral therapies, Ebola viruses are classified as hazard group 4 pathogens by the Advisory Committee on Dangerous Pathogens (ACDP). The Ebolavirus genus is one of three genera of the family Filoviridae. Currently, this genus is composed of five alternative species of the Ebola virus, which are associated with different pathogenicity and case fatality rates. Zaire Ebola virus (EBOV) is the most pathogenic for humans and causes sporadic outbreaks with fatality rates reaching up to 90%, while Reston Ebola virus (RESTV) is not pathogenic for humans. However, RESTV can cause viral hemorrhagic fever in nonhuman primates and illustrates the potential zoonotic threat of Ebola virus. 1−3 Ebola virus outbreaks occur irregularly, with the most recent outbreak occurring in West Africa in 2014, with fatality rates currently over 60%.
Ebola virus is an enveloped nonsegmented negative singlestranded RNA virus with a genome of 19kb in length consisting of seven genes encoding eight proteins: nucleoprotein (NP), virion protein (VP) 35, VP40, glycoprotein (GP), VP30, VP24, and the RNA-dependent RNA polymerase (L). The combination and action of these gene products and their interactions with the host cell cause the severe hemorrhagic fever. One of the proteins thought to contribute to disease pathology is VP24 and may be a major factor in virulence. 4 This protein is considered a secondary matrix protein as only a small amount of VP24 is incorporated into viral particles. However, VP24 has affinity for the plasma membrane and is associated with the envelope of the virion. VP24 has been shown to have several functions, including an involvement in viral nucleocapsid formation and the regulation of replication. 5, 6 Critically, VP24 is also involved in modulation of the host response to infection through evasion of the host immune response. VP24 may disrupt interferon signaling by binding to karyopherin-α (KNP-α), 7 which blocks the nuclear accumulation of tyrosine-phosphorylated STAT1 (PY-STAT).
8 STAT1 is a major signaling molecule involved in initiating the antiviral response. 9 Nuclear translocation of STAT1 is essential for transcriptional activation of numerous interferon responsive genes. VP24 can also inhibit IFN-α/β-and IFN-γ-induced gene expression. 10 The mechanism of action through which VP24 modulates the immune response is unknown. However, other work suggested that VP24 may be structurally similar to importin-α/β and exportin. 11 Thus, VP24 may be involved in the mimicry of host transporter/cargo interactions. 11, 12 Mutations in VP24 have been linked to the adaptation of Zaire Ebola virus in mice and guinea pigs to produce lethal disease. 13−15 Therefore, VP24 may form critical protein−protein interactions with host-cell proteins to modulate host-cell pathways; this is the case of the interaction of VP24 with karyopherin, which is required for the inhibition of the interferon-signaling pathway. Elucidating these interactions in detail would provide a deeper understanding of Ebola virus infection and also potentially present antiviral chemo-therapeutic targets to disrupt virus biology.
To determine which cellular proteins or complexes interact with VP24 and to predict function, we have used high-affinity purification coupled to a label-free mass-spectrometry-based approach. Using conservative selection criteria, approximately 50 cellular proteins were identified that had a high probability of interacting with VP24. Some of the candidate proteins had been identified in previous analyses, confirming that our approach was able to identify known interactions, thus increasing confidence that the analysis was capable of identifying new cellular proteins in the same experiment. One of the novel hits identified was sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1). This enzyme can be inhibited by the small-molecule inhibitor ouabain, which is used in the treatment of heart failure. We used this drug in experiments to inhibit the function of ATP1A1 in cells infected with Ebola virus. The data indicated that progeny virus decreased in treated infected cells compared with untreated infected cells.
■ EXPERIMENTAL PROCEDURES EGFP-VP24 and VP24-EGFP Construction
Codon-optimized (for expression in human cells) cDNA sequence encoding Zaire EBOV Mayinga Strain 1976 VP24 protein (NCBI reference sequence number: NP_066250.1) was cloned into the pEGFP-C1 and pEGFP-N1 vectors to generate Zaire EBOV VP24 with C-terminal EGFP tag and Nterminal EGFP tag; the plasmid sequences were confirmed by sequencing.
Cell Culture and Transfections
HEK 293T cells were grown in Dulbecco's modified Eagle's medium (DMEM; Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) and 1% penicillinstreptomycin (Sigma-Aldrich) at 37°C with 5% CO 2 . To transfect 293T cells, two 145 cm 2 dishes were seeded with 4 × 10 6 cells 24 h prior to calcium phosphate transfection with 25.6
μg of plasmid DNA encoding EGFP, EGFP-VP24, and VP24-EGFP, respectively. After 24 h post-transfection the cells were harvested, lysed, and immunoprecipitated using a GFP-Trap (Chromotek).
EGFP Coimmunoprecipitations
EGFP-VP24, VP24-EGFP, and EGFP immunoprecipitations were performed using a GFP-Trap_A (Chromotek), and cell pellet was resuspended in 200 μL of lysis buffer (10 mM Tris/ Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 0.5%NP40) supplemented with Halt Protease Inhibitor Cocktail EDTAFree (Thermo Scientific) and incubated for 30 min on ice. The lysate was clarified by centrifugation at 14 000g and diluted fivefold with dilution buffer (10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA) supplemented with Halt Protease Inhibitor Cocktail EDTA-Free (Thermo Scientific). The GFPTrap agarose beads were equilibrated with ice-cold dilution buffer supplemented with Halt Protease Inhibitor Cocktail EDTA-Free (Thermo Scientific) and then incubated with diluted cell lysate overnight at 4°C on a rotator, followed by centrifugation at 2700g for 2 min. The bead pellet was washed two times with wash buffer (10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA) supplemented with Halt Protease Inhibitor Cocktail EDTA-Free (Thermo Scientific). After the removal of wash buffer the beads were resuspended with 25 μL of elution buffer (200 mM Glycine pH 2.5) and incubated for 10 min at room temperature in a thermal shaker to elute bound proteins; the beads were then collected by centrifugation, and the eluted proteins were transferred to a 1.5 mL centrifuge tube. This step was repeated four times to ensure the maximum elution and all of the eluates were combined; 10 μL of Tris-base buffer (pH 10.4) was added to neutralize the eluate. Immunoprecipitated samples were then analyzed using labelfree mass spectrometry.
Reverse Coimmunoprecipitation
Immunoprecipitations for Karyopherin α6 and Lamin B1 were performed using the immobilized recombinant protein G resin (Generon) and specific antibodies against karyopherin α6 (E-11) (Santa Cruz Biotechnology; sc-390055) and Lamin B1 (ZL-5) (Santa Cruz Biotechnology; sc-56145). cell pellets were incubated for 30 min on ice with 200 μL of lysis buffer; the lysate was clarified by centrifugation and diluted five-fold with dilution buffer prior to adding 2 μg of the primary antibody and then incubated at 4°C on a rotator for 2 h. The protein G resin (Generon) was equilibrated with ice-cold dilution buffer and then incubated at 4°C on a rotator with diluted cell lysate containing the antibody overnight at 4°C on a rotator, followed by centrifugation at 2700g for 2 min to remove nonbounds. The wash and elution steps were preformed as previously described in GFP coimmunoprecipitation.
Label-Free Mass Spectrometry
Eluted samples were diluted two-fold with 25 mM ammonium bicarbonate. Rapigest (Waters) was added to a final concentration of 0.05% (w/v), and the sample was heated to 80°C for 10 min. Proteins were reduced with 3 mM dithiothreitol (Sigma) at 60°C for 10 min, then alkylated with 9 mM iodoacetimide (Sigma) at room temperature for 30 min in the dark. Proteomic grade trypsin (Sigma) was added (0.2 μg), and samples were incubated at 37°C overnight. The Rapigest was removed by adding TFA to a final concentration of 1% (v/v) and incubating at 37°C for 2 h. Peptide samples were centrifuged at 12 000g for 60 min (4°C) to remove precipitated Rapigest. Each digest was concentrated and desalted using C18 Stage tips (Thermo Scientific), then dried down using a centrifugal vacuum concentrator (Jouan) and resuspended in a 0.1% (v/v) TFA, 3% (v/v) acetonitrile solution.
Peptide mixtures (2 μL) were analyzed by online nano flow liquid chromatography using the nanoACQUITY-nLC system (Waters MS technologies, Manchester, U.K.) coupled to an LTQ-Orbitrap Velos (Thermo Fisher Scientific, Bremen, Germany) mass spectrometer equipped with the manufacturer's nanospray ion source. The analytical column (Nano ACQUITY UPLCTM BEH130 C18 15 cm × 75 μm, 1.7 μm capillary column) was maintained at 35°C and a flow-rate of 300nL/ min. The gradient consisted of 3−40% acetonitrile in 0.1% formic acid for 50 min then a ramp of 40−85% acetonitrile in 0.1% formic acid for 3 min. Full-scan MS spectra (m/z range 300−2000) were acquired by the Orbitrap at a resolution of 30 000. Analysis was performed in data-dependent mode. The top-20 most intense ions from MS1 scan (full MS) were selected for tandem MS by collision-induced dissociation (CID), and all product spectra were acquired in the LTQ ion trap.
Label-Free Analysis
Label-free quantitation was performed using MaxQuant (MQ) software (version 1.3.0.5.) with its internal search engine Andromeda. Precursor mass and fragment mass were searched with mass tolerance of 6 ppm and 0.5 Da, respectively. All other settings were default. The search included variable modifications of methionine oxidation and N-terminal acetylation and fixed modification of carbamidomethyl cysteine. Enzyme specificity was set to trypsin, minimal peptide length was set to seven amino acids, and a maximum of two mis-cleavages was allowed. The false discovery rate (FDR) was set to 0.01 for peptide and protein identifications. The Andromeda search engine was configured for a database containing human proteins (Uniprot release-2013_03) and VP24 GFP constructs (56601 entries). The MQ software further included a decoy database as well as containing common contaminants to determine the FDR and to exclude false-positive hits due to contamination by proteins from different species. For LFQ analysis, "multiplicity" was set to one. Feature matching between raw files was enabled using a retention time window of 2 min. "Discard unmodified counterpart peptides" was unchecked. Only unmodified and unique peptides were utilized. Averaged LFQ intensity values were used to calculate protein ratios.
Bioinformatics Analysis
Label-free mass spectrometry results were processed and analyzed using the Perseus software (MaxQuant); this software was used to perform the statistical analysis and to differentiate background proteins (those cellular proteins that interacted with EGFP alone) from interacting proteins (those cellular proteins that interacted with EGFP-VP24 or VP24-EGFP). LFQ intensity values were analyzed using a T-Test. A volcano plot graphic and a table were generated showing the statistical significant proteins, those proteins that had a high probability of interacting with VP24. The String 9.05. program was used to predict the protein−protein interactions of the statistically significant proteins and also to group proteins according function.
Western Blot Analysis
Beads were then resuspended and boiled in 100 μL of 2× SDSsample buffer at 95°for 10 min to elute the bound proteins. The beads were then collected by centrifugation, and SDS-PAGE was preformed with the supernatant (elution faction). 10% SDS polyacrylamide gels were used to perform the SDS-PAGE; then, gels were transferred to PVDF membranes (Millipore) using a semidry transfer system. Transferred membranes were blocked in 5% skimmed milk powder dissolved in TBS-0.1% Tween (TBS-T) (50 mM Tris-HCl (pH8.3), 150 mM NaCl, and 0.5% (v/v) Tween-20) buffer for 60 min at room temperature. Primary antibody was diluted 1:1000 in blocking buffer and then incubated at 4°C overnight; antibodies used against GFP (Santa Cruz Biotechnology; sc-8334), karyopherin α6 (E-11) (Santa Cruz Biotechnology; sc-390055), Lamin B1 (ZL-5) (Santa Cruz Biotechnology; sc-56145), and Na + /K + -ATPase α (H-3) (Santa Cruz Biotechnology; sc-48345) were from Santa Cruz, and anti-VDAC1/porin antibody was from Abcam (Abcam; ab14734). After three washes, blots were incubated with appropriate HRP secondary antibody diluted in blocking buffer at a 1:2000 for 1 h at room temperature. Blots were developed using enhanced chemiluminesence reagent (BioRad) and detected using a BioRad Imaging system. September 23, 1976 , in Yambuku, Equateur Province Zaire. This strain is equivalent to the Mayinga strain, as Sister M.E. nursed Sister Mayinga (who the strain is named after) and most likely contracted her infection. Leibovitz's L-15 media containing 2% fetal bovine serum was added, and the infected cells were incubated at 37°C for 1 h. In triplicate flasks, Ouabbain Octahydrate (Sigma; O3125) was added to the media to a final concentration of 20 nM; a further three flasks were left as an untreated control. At 24 and 48 h postinfection, a sample of media from each flask was added to AVL inactivation buffer (Qiagen; 19073) prior to removal from the Containment Level 4 (CL4) laboratory for nucleic acid extraction. The QIAamp Viral RNA Mini Kit from Qiagen (cat. no. 52904) was used for nucleic acid extraction, as this facilitated transport of the nucleic acid samples from CL4 to CL2. Following the extraction of viral RNA, the cDNA was synthesized using specific primers against the gene encoding the nucleoprotein of Zaire Ebola virus. The cDNA was synthesized using the Thermo Script RT-PCR System from Invitrogen (cat. no. 11146-024) following the manufacturer's instructions. PCR was performed with Paq5000 DNA polymerase (Agilent Technologies) (data not shown). Finally, a qPCR was performed to compare the RNA levels in the infected cells treated and untreated with Ouabain experiment. This was performed with the iTaq Universal SYBR Green Supermix (BIO RAD).
■ RESULTS

Expression of VP24 in 293T Cells
To obtain a more complete picture of the interaction partners of VP24, we used quantitative proteomics coupled to an immunoprecipitation strategy based on expressing VP24 as an EGFP-fusion in human 293-T cells and utilizing a GFP-trap to selectively precipitate the fusion protein and interacting partners ( Figure 1A ). 293-T cells are derived from embryonic kidney cells and were chosen due to their ability to sustain Ebola virus replication, their high transfection efficiencies using calcium-phosphate, and the well-annotated human databases that aid with protein identification and function assignment. To identify interacting cellular partners specific for VP24, we used label-free LC−MS/MS to analyze binding partners from cells expressing either EGFP or the EGFP-VP24 or VP24-EGFP fusion proteins. Subsequent comparison of the immunoprecipitated interacting partners from these conditions allowed the identification of cellular components that specifically bound to the VP24 moiety within the EGFP/VP24 fusion protein. This general approach has been shown to improve sensitivity and allow discrimination of specific from nonspecific interactions with the target protein 16, 17 and can be readily applied to the analysis of the cellular interactomes of viral proteins. 18−20 To identify cellular proteins that interact with VP24, we cloned the gene encoding EGFP either 5′ or 3′ of a gene encoding codon-optimized VP24 from a virus similar to the Zaire EBOV, Mayinga Strain 1976, such that when the construct was transfected in cells the EGFP moiety was expressed as either an N-or C-terminal fusion of VP24, respectively. In this way, we mitigated against potential nonbinding to cellular targets caused by steric hindrance of the EGFP moiety. Proteins were precipitated using the anti-EGFP antibody, and both input (cell lysate) and eluted fraction were compared using immunofluoresence ( Figure 1B ) and Western blot ( Figure 1C ). The data indicated that both EGFP-VP24 and VP24-EGFP were expressed with high efficiency at the expected molecular weight (∼55 kDa).
Identification of the Potential Cellular Interacting Partners of VP24
EGFP-VP24, VP24-EGFP, and EGFP were then overexpressed in 293T cells, and the cellular binding partners were immunoprecipitated using the GFP-trap. These proteins were identified by mass spectrometry. To differentiate those cellular proteins that formed specific interactions with VP24 versus those proteins that interacted with EGFP or formed nonspecific interactions with the binding matrix, we repeated the immune precipitations and mass spectrometry five times. Approximately 600 cellular proteins were initially identified and quantified, which represented both the specific and nonspecific interactions. To differentiate between these possibilities, we took several conservative processing steps. The 15 data sets were analyzed by the Perseus software algorithm. Proteins identified by a single peptide were removed, and a p value was set at <0.01 for the t-test analysis, where theoretically only 1:100 proteins were misidentified. The data were then organized in the form of volcano plots for EGFP-VP24 and VP24-EGFP ( Figure 2A ,B, respectively). These show P values (−log 10 ) for confidence in peptide identification versus fold difference in binding of a protein between the VP24 fusion protein and EGFP only. Dots represent individual proteins. Those dots inside the volcano plots represent proteins that did not associate with VP24 with statistical significance. Proteins that had a binding ratio greater than 2 and were statistically significant are shown in the right-hand quadrant. For EGFP-VP24 and VP24-EGFP, 48 and 51 proteins (Table 1 ), Figure 1 . Expression of VP24 in 293T cells. (A) Schematic representation of the methodology used in this study. HEK 293T cells were grown in DMEM supplemented with 10% FBD and 1% penicillin-streptomycin at 37°C with 5% CO2. Two 145 cm 2 dishes were seeded with 4 × 10 6 cells 24 h prior to calcium phosphate transfection with 25.6 μg of plasmid DNA encoding EGFP, EGFP-VP24, and VP24-EGFP, respectively. 24 h post-transfection the cells were harvested, lysed, and immunoprecipitated using a GFP-Trap (Chromotek). Label-free mass spectrometry analysis on the eluted samples was then carried out. (B) Expression of VP24-EGFP, EGFP-VP24, and EGFP in 293T cells was confirmed by immunofluorescence using confocal microscopy and DAPI (blue) to counterstain the nucleus; the panels show that expression of two constructs were similar (however, EGFP-VP24 shows a higher expression than VP24-EGFP) and that approximately 50% of cells were transfected. (C) Analysis of the pull-down products using a Western blot confirm the presence of EGFP-VP24, VP24-EGFP, and EGFP with the expected molecular weight, confirming the expression of these proteins in 293T cells.
respectively, were identified as interacting with statistical significance. Both fusion proteins had 40 proteins identified in common; 8 proteins were unique for EGFP-VP24 and 11 proteins were unique for VP24-EGFP. A map of these protein− protein interactions was performed using the String Algorithm (version 9.05) and is presented in Figure 3 .
Cellular proteins that had a higher statistical likelihood of associating with VP24 included importin subunit alpha 1 and 6 (karyopherin-α1 and karyopherin-α6), lamin B1, VDAC-1, and ATP1A1. Importin α1 has been previously shown to interact with VP24 8 and therefore indicated that our approach identified Protein Abundance Across Organisms database) (Table 1) indicated that the likelihood of binding was not proportional to their abundance in a cell, thus increasing confidence that the amount of binding was not merely a reflection of overall protein abundance. Shown are candidate proteins identified using the EGFP-VP24 (A) and VP24-EGFP (B) fusion proteins and identified using label-free quantitative proteomics. Protein identifier, protein name, and gene names are indicated. Total and unique peptides used to identify the protein are indicated. The −Log P value is a comparison of the cellular protein between the VP24 pull down and EGFP, where the higher the number means the higher probability of interacting, and a threshold above 2.0 has been selected. The fold-change or fold-difference between the two conditions the VP24-EGFP or EGFP-VP24 versus the EGFP alone is indicated. PEP is the posterior error probability, and percentage of sequence coverage of the protein identified using the peptides is indicated as SC%. The abundance (ppm) of the protein in an average human cell is listed; data are taken from the PaxDb: Protein Abundance Across Organisms database. Indicated is a brief summary of the function and the subcellular localization of each possible interactor partner.
Validation of VP24-EGFP and EGFP-VP24 Interactions
Selected cellular targets identified in the immune-precipitations to VP24 were then investigated using Western blot as an alternative means of identification ( Figure 4A ). These targets included karyopherin α6 (as a positive control), ATP1A1, lamin B1, and VDAC-1. The presence of STAT1 was also investigated; even though it had not been identified in the immunoprecipitation, as purified truncated STAT1 and purified truncated VP24 had previously been shown to associate in vitro. 21 Whole cell lysate (input) and eluate (elution) from separate immunoprecipitations were separated by 1D SDS-PAGE; proteins were then transferred in Western blot and detected using a primary antibody against each selected protein.
The data indicated that karyopherin α6, lamin B1, and ATP1A1 associated with both the EGFP-VP24 and VP24-EGFP moieties. By Western blot, VDAC1 appeared to have a greater association for EGFP-VP24 than VP24-EGFP. Although STAT1 could be detected in the input fractions, it was not detected in the immunoprecipitations ( Figure 4A ). To further validate the mass spectrometry results and potential interactions between VP24 and cellular proteins, we performed reverse immunoprecipitations against selected cellular targets where antibody combinations allowed. These targets were karyopherin α6 (as a positive control) and lamin B1. VP24-EGFP, EGFP-VP24, or EGFP were expressed in 293T cells and cell lysates were prepared. Immunoprecipitations were performed using specific monoclonal antibodies against karyopherin α6 and lamin B1. Analysis of the pull-down products using a Western blot confirmed the presence of EGFP-VP24, VP24-EGFP, and EGFP in the input and elution fraction. The presence of EGFP-VP24 and VP24-EGFP was To further validate the mass spectrometry results, we performed reverse immunoprecipitations against selected cellular proteins identified by the label-free mass spectrometry analysis. The selected proteins for the validation of the label-free mass spectrometry by using reverse immunoprecipitations were karyopherin α6 and lamin B1; the presence of the protein complex EGFP-VP24 and VP24-EGFP was confirmed using a Western blot analysis and using a specific antibody against EGFP.
confirmed using a specific antibody against EGFP ( Figure 4B ), again validating the forward immunoprecipitations.
Inhibition of ATP1A1 in Ebola Virus Infected Cells
To investigate whether ATP1A1 played a functional role in Ebola virus infected cells, we used the small molecule inhibitor to ATP1A1, ouabain, to treat human MRC-5 cells infected with EBOV strain ME718 (MOI = 0.1). This fibroblast lung culture was established from a 14-week gestation human male and is a normal diploid cell line that supports the growth of Ebola virus and has been used in antiviral drug screening studies. 22 Cell viability assays were used to determine the affect of different concentrations of ouabain on cell biology and included two other small-molecule inhibitors (17-AAG and W-7) as positive controls ( Figure 5A ). The data indicated that both 10 and 20 nM ouabain had no significant effect on cell viability compared with either untreated or cells treated with the vehicle (DMSO) only control. The 20 nM concentration of ouabain also had no apparent effect on the abundance of EGFP-VP24 in treated cells expressing this construct ( Figure 5B ). Cells were either infected and untreated or infected and treated with 20 nM ouabain to determine the potential effect of this drug on Ebola virus infection. The experiment was repeated in triplicate, and the use of a consistent volume of cell culture supernatant permitted the comparison of the relative abundance of the Ebola virus genome in the supernatant as a proxy measurement for virus particles. 23, 24 Therefore, equal volumes of supernatant containing progeny virus were taken at 24 and 48 h postinfection. Viral RNA was then isolated and RNA levels were compared in triplicate using qRT-PCR between each treatment at 24 and 48 h post infection; data were normalized to the level of viral RNA in infected but untreated cells ( Figure  5C ). Results indicated that infected cells treated with 20 nM ouabain produced less viral RNA compared with infected but untreated cells.
■ DISCUSSION
The genomes of RNA viruses have limited encoding capacity, and therefore viral proteins usually possess multiple functions in the cell and virus life cycle. The elucidation of these interactions provides a better understanding of viral pathogenesis and delivers more options for effective antiviral strategies. Ebola virus VP24 has been shown to have multiple functions in the virus life cycle and therefore would be predicted to interact with a variety of different cellular proteins. Several studies have investigated this with data suggesting that VP24 can interact with karyopherin α, STAT1, and Sec61α. 10, 21, 25 In this study, affinity tagging coupled to labelfree quantitative mass spectrometry was used to identify potential interacting partners of VP24 and reduce or eliminate false-positive interactions. Approximately 50 cellular proteins were identified that had a high probability of interacting with VP24. The majority of proteins identified associated with either EGFP-VP24 or VP24-EGFP. However, some of the cellular proteins identified were unique to the different fusion proteins. This may have been due some of the interactions with the cellular proteins being sterically hindered by the EGFP moiety and emphasized the advantage of using both the N-and Cterminal tagged fusion proteins.
VP24 has affinity for the plasma membrane and has also been observed in the cytoplasm where the protein formed cytoplasmic inclusions. 26 These are the cellular locations of a number of the proteins identified as associating with VP24 ( Table 1 ). The reliability of this mass spectrometry data was confirmed using Western blot analysis and reverse immunoprecipitations against selected cellular proteins. Furthermore, the precipitations and mass spectrometry analysis were repeated five times with independent samples to ensure the reproducibility of the technique and also for the statistical analysis. The immunoprecipitation technique was also optimized for identifying low-affinity and transient interactions by modulating the salt concentration in the washing step.
Karypherin α subunit 6 (KPNA6) and 1 (KPNA1), identified in this study with an average binding ratio of 8 to both EGFP-VP24 and VP24-EGFP, reflected previous work demonstrating an interaction between EBOV-VP24 and karypherin α subunit 6. 8, 10 In addition, as part of a larger viral/host protein study, the interactome of VP24 was determined using tandem affinity purification, and KPNA6 and other karypherins were identified as part of 48 cellular proteins that potentially interacted with VP24. 27 Proteins in common with this previous work and recorded in our analysis as having a greater than two-fold abundance with either EGFP-VP24 or VP24-EGFP were ANP32A, ANP32B, CCAR2 (KIAA1967), CGGBP1, HNRNPL, HNRNPU, KPNA1, KPNA6, MYO5A, POM121C, PRKCSH, RPS27, RPS27L, SLC25A3, TUB1C, and TUBB, 28 proteins were not detected in our study, and three proteins (EEF1A1, EEF1A2, and SPOP) were identified as proteins that formed background/nonspecific interactions.
In the present study, no interaction was detected between VP24 and STAT1 using the mass spectrometry approach, and this was confirmed by Western blot. Likewise, no interaction between VP24 and STAT1 was described in the tandem affinity approach. 27 This differs from previously published work that described an interaction between VP24 and STAT1. 21 However, the difference in these results may be due to different systems employed. In the previously published work, the interaction between EBOV VP24 and STAT1 was determined by ELISA using purified truncated forms of VP24 and STAT1. 21 In the present study, the EGFP moiety may have prevented interaction with STAT1, likewise with the tandem affinity approach described previously, 27 although the tag did not prevent interaction with the karyopherins and other cellular proteins.
Sec61α was not listed in the final data set, but proteins that form a complex with Sec61α were identified, including SSR4 and Sec61B. Notably, Sec61B has been formally demonstrated to be significant using biological approaches. 25 Indeed, Sec61B protein was found in one of the trial runs of this study but excluded after the statistical analysis of the five independent mass spectrometry analyses of EGFP-VP24 and VP24-EGFP. This suggests that in the case of Sec61B our selection criteria was too conservative or affected by the EGFP moiety or the interaction with Sec61α may be a weaker or more transient interaction than those listed in Table 1 . Although, we note that the interaction between VP24 and Sec61α was identified using a tandem tagging approach of VP24 25 but was not identified in a more recent study. 27 One cellular protein with a high binding ratio was ATP1A1, a Na+/K+-ATPase. The function of this protein is in establishing and maintaining Na + and K + electrochemical gradients across the plasma membrane and in cell signaling. Inhibiting the function of ATP1A1 with ouabain resulted in a decrease in progeny virus. Ouabain is used in treating atrial fibrillation and heart failure and has been demonstrated to have antiviral effect with other viruses including herpes simplex virus 28 and porcine reproductive and respiratory syndrome virus. 29 The effect of ouabain on ATP1A1 may not have had a direct effect on the relationship between ATP1A1 and VP24. For example, treatment of cells infected with human cytomegalovirus with ouabain prevented enlargement of cells that is associated with progeny virus production. 30 Nevertheless, the use of this small molecule to reduce progeny virus in Ebola-virus-infected cells illustrates how existing therapeutics can be repurposed for antiviral therapy. In the case of a natural infection in humans, even a modest reduction in viral progeny production in vivo may slow the virus sufficiently for the host immune response to mount a life-saving response.
To our knowledge, this is the first detailed interactome analysis of VP24 using quantitative proteomics to identify cellular proteins that have a high probability of interacting with VP24 and to eliminate or identify cellular proteins that potentially associate with a binding matrix used in immunoprecipitations. The current study complements previous work that used small molecules to inhibit the function of cellular proteins to disrupt Ebola virus biology. For example, Sadenosylhomocysteine hydrolase inhibitors were evaluated both in vitro and in vivo and were detrimental to Ebola virus infection. 22 Inhibition of heat shock protein 90 using 17-AAG disrupted Ebola biology in vitro 31 At the time of publication of this manuscript, the largest EBOV outbreak so far known is occurring in West Africa and has proved difficult to control; the "repurposing" of therapeutics to reduce virus infection may tip the balance between recovery and death.
Overall, the proteomic approach demonstrated how determining the interactome of viral proteins can be used to identify cellular proteins that play important roles in the virus lifecycle and therefore increase the repertoire of potential drugable targets. Resistance is a constant problem in developing antiviral therapy to target the function of viral proteins. Transiently targeting the function of host cell proteins crucial to virus biology offers an exciting new therapeutic avenue, with the potential to solve the problem of resistance, as pro-viral cellular proteins are evolutionarily static on the time scale of lytic virus replication as well as separated from the genome that would benefit from resistance. 
